Drug Search Results
More Filters [+]

Ferric citrate

Alternative Names: ferric citrate, krx-0502, krx 0502, krx0502, auryxia
Latest Update: 2024-10-10
Latest Update Note: News Article

Product Description

Ferric citrate (FC) is an iron-containing phosphate binder that has been shown to effectively decrease serum phosphate, increase hemoglobin, and replete iron stores in patients with chronic kidney disease. Intestinal absorption of iron from FC results in increases in serum iron, ferritin, and transferrin saturation, effects that occur over 12 to 24 weeks and subsequently appear to plateau.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27236135/)

Mechanisms of Action: TFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Brazil | European Medicines Agency | Hungary | Ireland | Italy | Japan | Latvia | Lithuania | Pakistan | Poland | Portugal | Sweden | Switzerland | Taiwan | Turkey | United States

Approved Indications: Kidney Diseases

Known Adverse Events: Constipation | Diarrhea

Company: Akebia
Company Location: CAMBRIDGE MA 02142
Company CEO: John P. Butler
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ferric citrate

Countries in Clinic: China, Taiwan, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Anemia|Anemia, Iron-Deficiency|Deficiency Diseases|Hyperphosphatemia|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

KRX-0502-309

P3

Not yet recruiting

Deficiency Diseases|Anemia, Iron-Deficiency|Kidney Failure, Chronic

2027-01-01

49%

KRX-0502-308

P3

Recruiting

Hyperphosphatemia|Kidney Failure, Chronic

2025-01-01

49%

FRONTIER

P3

Completed

Hyperphosphatemia|Anemia, Iron-Deficiency|Kidney Failure, Chronic

2024-01-24

PBB00601

P3

Completed

Anemia|Kidney Failure, Chronic

2022-10-28

49%

Recent News Events